Compositions and methods for treating chronic inflammation and inflammatory diseases

1. A method of treating an individual with a chronic inflammation, the method comprising the step of: administering to the individual in need thereof a pharmaceutical composition, the pharmaceutical composition comprising:

a) about 10% to 30% of a propionic derivative NSAID by weight of the pharmaceutical composition;

b) about 5% to about 15% of a polyethylene glycol (PEG) polymer by weight of the pharmaceutical composition, the pharmaceutically-acceptable PEG polymer being less than about 2,000 g/mol;

c) about 20% to about 50% of a hard fat by weight of the pharmaceutical composition, the hard fat comprising a triglyceride or a triester of glycerol; and

d) about 10% to about 30% of a liquid fat by weight of the pharmaceutical composition, the liquid fat comprising a monoglyceride,

wherein the pharmaceutical composition is formulated to be a solid at a temperature of about 15° C. or lower and have a melting point temperature in the range of about 25° C. or higher, and

wherein administration results in a reduction in a symptom associated with the chronic inflammation, thereby treating the individual.

2. The method according to claim 1 , wherein the propionic acid derivative NSAID is about 20% to about 30% by weight of the pharmaceutical composition.

3. The method according to claim 2 , wherein the propionic acid derivative NSAID is in an amount from about 25% to about 30% by weight of the pharmaceutical composition.

4. The method according to claim 1 , wherein the propionic acid derivative NSAID comprises an Alminoprofen, a Benoxaprofen, a Dexketoprofen, a Fenoprofen, a Flurbiprofen, an Ibuprofen, an Indoprofen, a Ketoprofen, a Loxoprofen, a Naproxen, an Oxaprozin, a Pranoprofen, or a Suprofen.

5. The method according to claim 1 , wherein the propionic acid derivative NSAID is a pharmaceutically-acceptable form of an Ibuprofen.

6. The method according to claim 1 , wherein the hard fat is in an amount from about 30% to about 50% by weight of the pharmaceutical composition.

7. The method according to claim 6 , wherein the hard fat is in an amount from about 35% to about 45% by weight of the pharmaceutical composition.

8. The method according to claim 1 , wherein the hard fat has a melting point of about 40° C. to about 46° C.

9. The method according to claim 8 , wherein the hard fat comprises a mixture of saturated C10-C18 triglycerides having a melting point of between 41° C. to 45° C.

10. The method according to claim 9 , wherein the hard fat comprises a mixture of saturated C10-C18 triglycerides having a melting point of about 43° C.

11. The method according to claim 1 , wherein the liquid fat is in an amount from about 15% to about 25% by weight of the pharmaceutical composition.

12. The method according to claim 1 , wherein the liquid fat further comprises a diglyceride, a triglyceride, or any combination thereof.

13. The method according to claim 1 , wherein the monoglyceride—is glyceryl monolinoleate.

14. The method according to claim 1 , wherein the PEG polymer is in an amount from about 8% to about 15% by weight of the pharmaceutical composition.

15. The method according to claim 14 , wherein the PEG polymer is in an amount from about 7% to about 13% by weight of the pharmaceutical composition.

16. The method according to claim 15 , wherein the pharmaceutically-acceptable PEG polymer is in an amount from about 8% to about 12% by weight of the pharmaceutical composition.

17. The method according to claim 16 wherein the PEG polymer is in an amount from about 9% to about 11% by weight of the pharmaceutical composition.

18. The method according to claim 1 , wherein administration is topical, enteral or parenteral.

19. The method according to claim 1 , wherein the chronic inflammation is a tissue inflammation or a systemic inflammation.

20. The method according to claim 1 , wherein the chronic inflammation is due to an auto-immune disease or a non-autoimmune disease.